Citations

Clear

133 citation(s) found for "Fernandes, B C".

3d Models as a Source for Neuroanatomy Education: a Stepwise White Matter Dissection Using 3d Images and Photogrammetry Scans
Oliveira, André de Sá Braga , Fernandes, João V, Figueiredo, Vera Louise Freire de Albuquerque , Leonel, Luciano, Link, Michael J. , Peris‐Celda, Maria , Bauman, Megan M. J.

Mayo Clinic

No container title available | January 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3895027/v1 Get It

Abstract White matter dissection (WMD) involves isolating bundles of myelinated axons in the brain and serves to gain insights into brain function and neural mechanisms underlying neurological disorders. While effective, cadaveric brain dissections pose certain challenges mainly due to availability of resources. Technological advancements, such as photogrammetry, have the potential to overcome these limitations by creating detailed three-dimensional (3D) models for immersive learning experiences in neuroanatomy. Objective: This study aimed to provide a detailed step-by-step WMD captured using two-dimensional (2D) images and 3D models (via photogrammetry) to serve as a comprehensive guide for studying white matter tracts of the brain. One formalin-fixed brain specimen was utilized to perform the WMD. The brain was divided in a sagittal plane and both cerebral hemispheres were stored in a freezer at -20°C for 10 days, then thawed under running water at room temperature. Micro-instruments under an operating microscope were used to perform a systematic lateral-to-medial and medial-to-lateral dissection, while 2D images were captured and 3D models were created through photogrammetry during each stage of the dissection. Dissection was performed with comprehensive examination of the location, main landmarks, connections, and functions of the white matter tracts of the brain. Furthermore, high-quality 3D models of the dissections were created and housed on SketchFab®, allowing for accessible and free of charge viewing for educational and research purposes. Our comprehensive dissection and 3D models have the potential to increase understanding of the intricate white matter anatomy and could provide an accessible platform for the teaching of neuroanatomy.
Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies
Li, Yafang , Xiao, Xiangjun , Li, Jianrong , Han, Younghun , Cheng, Chao , Fernandes, Gail , Slewitzke, Shannon E. , Rosenberg, Susan M. , Zhu, Meng , Byun, Jinyoung , McKay, James , Lam, Stephen , Chen, Chu , Bojesen, Stig E. , Landi, Maria Teresa , Risch, Angela , Wichmann, H-Erich , Goodman, Gary E. , Field, John K. , Shete, Sanjay , Liu, Geoffrey , Andrew, Angeline S. , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan , Purrington, Kristen S. , Liu, Yanhong , Mandal, Diptasri , Gaba, Colette , Brennan, Paul , Xia, Jun , Fernandes, Gail F , Bossé, Yohan , McKay, James , Albanes, Demetrius , Lam, Stephen , Tardón, Adonina , Chen, Chu , Bojesen, Stig E , Landi, Maria T , Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Wichmann, H-Erich , Christiani, David C. , Rennert, Gad , Arnold, Susanne M , Goodman, Gary E , Field, John K , Davies, Michael P A , Shete, Sanjay , Marchand, Loïc Le , Liu, Geoffrey , Hung, Rayjean J , Andrew, Angeline S , Kiemeney, Lambertus A , Sun, Ryan , Zienolddiny, Shanbeh , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E , Cox, Angela , Hong, Yun‐Chul , Lazarus, Philip J. , Schabath, Matthew B , Aldrich, Melinda C , Schwartz, Ann G , Gorlov, Ivan , Purrington, Kristen S , Yang, Ping , Liu, Yanhong , Wilson, Richard K , Pinney, Susan M , Mandal, Diptasri , Willey, James C , Brennan, Paul , Xia, Jun , Shen, Hongbing , Amos, Christopher I , Han, Younghun , Cheng, Chao , Byun, Jinyoung , Bossé, Yohan , Albanes, Demetrius , Tardón, Adonina , Johansson, Mattias , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Marchand, Loı̈c Le , Hung, Rayjean J. , Kiemeney, Lambertus A. , Zienolddiny, Shanbeh , Cox, Angela , Schabath, Matthew B. , Yang, Ping , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Willey, James C. , Shen, Hongbing , Amos, Christopher I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 5, 2024 | Volume: 33 | Issue: 3 | Pages: 389-399

10.1158/1055-9965.epi-23-0613 | PMID 38180474 Get It

Abstract Background: Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer. Methods: We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer. Results: Five novel independent loci, GABRA4, intergenic region 12q24.33, LRRC4C, LINC01088, and LCNL1 were identified with the association at two or three populations (P < 5 × 10−8). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage (GABRA4) or cis-regulation of gene expression (LCNL1). The risk of variants from 12 independent regions, including the well-known CHRNA5, associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear > 20). Different risk patterns were observed for the variants among the different groups by smoking behavior. Conclusions: We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies. Impact: Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.
Advances in MRI-Based Assessment of Rectal Cancer Post-Neoadjuvant Therapy: A Comprehensive Review
Miranda, João , Andrieu, Pamela Causa , Ninčević, Josip , Khasawneh, Hala , Arita, Yuki , Stanietzky, Nir , Fernandes, Maria Clara , Castria, Tiago Biachi De , Horvat, Natally , Causa Andrieu, Pamela , Khasawneh, Hala , Arita, Yuki , Fernandes, Maria Clara , Biachi de Castria, Tiago , Horvat, Natally , Farias, Lucas de Pádua Gomes de

Mayo Clinic

Journal of Clinical Medicine | December 28, 2023 | Volume: 13 | Issue: 1 | Pages: 172

10.3390/jcm13010172 | PMID 38202179 Get It

Rectal cancer presents significant diagnostic and therapeutic challenges, with neoadjuvant therapy playing a pivotal role in improving resectability and patient outcomes. MRI serves as a critical tool in assessing treatment response. However, differentiating viable tumor tissue from therapy-induced changes on MRI remains a complex task. In this comprehensive review, we explore treatment options for rectal cancer based on resectability status, focusing on the role of MRI in guiding therapeutic decisions. We delve into the nuances of MRI-based evaluation of treatment response following neoadjuvant therapy, paying particular attention to emerging techniques like radiomics. Drawing from our insights based on the literature, we provide essential recommendations for post-neoadjuvant therapy management of rectal cancer, all within the context of MRI-based findings.
Alzheimer’s disease‐associated post‐translational modifications of tau influence tau propagation
Fan, Zhanyun, Dickson, John R. , Fernandes, Analiese R. , Sobolewski, Robert, Hyman, Bradley T.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S13 | Pages: No page available

10.1002/alz.080107 Get It

AbstractBackgroundIn Alzheimer’s disease (AD), tau accumulates with a stereotyped progressive involvement of brain regions. The cellular mechanism for this is the neuron‐to‐neuron propagation of tau, but the factors that influence tau propagation are not fully understood. We hypothesize that AD‐associated post‐translational modifications (PTMs) of tau reduce its propagation since lysines are critical for LRP1‐mediated tau uptake.MethodA construct was designed to model tau propagation in Chinese hamster ovary (CHO) cells and allow identification of donor and recipient cells by immunocytochemistry and flow cytometry. In addition to the wildtype (WT) tau sequence, constructs were made with pseudophosphorylation and pseudoacetylation mutations corresponding to the phosphorylations and acetylations found on low molecular weight (LMW) and high molecular weight (HMW) tau species in AD brains. Additionally, individual PTM mimic mutations corresponding to PTMs of the LMW tau species were made. The constructs were transfected into CHO cells and tau propagation was assessed by flow cytometry after 48 hours. Statistical analysis was performed by ANOVA with adjustment for multiple comparisons.ResultTau propagation using this cell culture model was demonstrated by immunocytochemistry and flow cytometry. Comparison of the WT, LMW‐mimic (8D2Q mutant), and HMW‐mimic (20D3Q mutant) tau propagation constructs revealed that the 8D2Q and 20D3Q mutants displayed reduced tau propagation compared to WT by 23.7% (p = 0.0186) and 26.5% (p = 0.0087), respectively. Comparing the ten single mutant constructs to WT, T181D and T231D showed increased tau propagation by 20.3% (p = 0.0002) and 15.9% (p = 0.0094), respectively. Compared to WT, T217D, K281Q, K353Q, and S404D showed reduced tau propagation by 17.3% (p = 0.0030), 15.3% (p = 0.0123), 23.7% (p <0.0001), and 16.6% (p = 0.0046), respectively.ConclusionThe mimics of AD‐associated tau PTMs found on LMW and HMW tau reduce tau propagation, consistent with the initial hypothesis. The impact of individual PTM mimics on tau propagation is variable, but notably both pseudoacetylation mimics reduce propagation, possibly due to lower affinity with LRP1. Understanding how AD‐associated tau PTMs impact tau propagation may suggest novel targets to slow the progression of AD pathology.
Inflammatory diabetic neuropathy: helpful diagnostic parameters (P5.132)
Thaisetthawatkul, Pariwat , Fernandes, J. Americo, Piccione, Ezequiel, Truong, Laetitia, Dyck, P. James B.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p5.132 Get It

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS
Harrison, Cynthia , Biery, D. N. , Zerkalenkova, Elena , Alonso‐Saladrigues, Anna , Utley, Kaylyn, Fernandes, Sneha, Carapia, Naomi Torres, Vatsayan, Anant , Pacenta, Holly , Escherich, Gabriele , Lee, Benjamin J. , Fitzjohn, Mandi R., Larson, Daniel P. , Cuevo, Raymund S., He, Rui , Reed, Kelly, Wölfl, Matthias , Raikar, Sunil S. , Savaşan, Süreyya , Puri, Latika, Gahvari, Zhubin, Talleur, Aimee C. , Abdel‐Azim, Hisham , Chamdin, Aghiad, Provost, Marlie R. M., Mezger, Kerstin, Stevens, Alexandra M. , Hsieh, Emily M. , Duffner, Ulrich, Hoang, Chloe, Davis, Kara L. , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Raikar, Sunil S , Zerkalenkova, Elena , Harrison, Cynthia , Lee, Benjamin J , Davis, Kara L , Silbert, Sara K. , Semchenkova, Alexandra , Aldoss, Ibrahim , Zhao, Liping , Rubinstein, Jeremy , Chang, Bill H , De Moerloose, Barbara , Kuo, Dennis J , Redell, Michele S. , Duployez, Nicolas , Dickens, David S. , Chaer, Firas El , Fabrizio, Vanessa A , Wang, Hao‐Wei , Yuan, Constance M. , Pan, Jing , Ghorashian, Sara , Rives, Susana , Shah, Nirali N

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4202-4202

10.1182/blood-2023-182293 Get It

Introduction: Lineage switch (LS) refers to the transformation of acute leukemia from one cell lineage to another (e.g., lymphoid (ALL) to myeloid (AML)). This rare phenomenon, distinct from treatment induced malignancy (i.e., t-AML) and mixed phenotype acute leukemia (MPAL), is increasingly being observed following cell surface antigen targeting. Given challenges in the diagnosis and treatment of LS, Project EVOLVE was developed to globally identify cases of LS following immunotherapy. Methods: A protocol and data collection form for this IRB exempt study was widely disseminated to capture deidentified LS case information across multiple centers and cancer consortia. This included collection of data from published reports of LS, with authors contacted to obtain additional information. For this analysis, LS was defined by the emergence of cell-surface markers warranting reclassification of the original leukemia as a different lineage derivation based on the immunophenotype, including cases of AML emerging alongside the original ALL. “Confirmed” LS cases included those where retention of original cytogenetic or molecular aberrations and/or the clonal immunoglobulin rearrangement patterns were verified to confirm the clonal relationship. “Suspected” LS cases included those where samples to confirm clonality marker retention could not be obtained, but the clinical presentation was consistent with LS. The term “transition” was applied when immunophenotypic shifts were transient. Cases with new cytogenetic abnormalities unrelated to the original diagnosis and compatible with t-AML were excluded. Statistical analysis was primarily descriptive. Data cut-off was July 26, 2023. Results: A total of 58 cases were identified, including 19 cases referenced in prior publications. Of the 58, 11 cases were excluded from this initial analysis, including: 4 cases of t-AML, 2 cases of T-ALL to AML, and 5 “transition” cases. Collectively, 47 cases of LS (43 “confirmed”; 4 “suspected”), spanning across 3 continents and 8 countries, were analyzed. (Fig. 1A) Cases included transition from B-ALL to AML in 36 (76.6%) and to MPAL/biphenotypic/ambiguous lineage in 11 (23.4%). Two likely had MPAL at diagnosis and a third with chronic myeloid leukemia. The median age at initial diagnosis was 8.4 years (range, 1 day-76.5 years); median age at LS presentation was 11.0 years (range 0.4-77.3 years). Twenty-three (48.9%) were male and 19 (40.4%) had prior stem cell transplant (SCT). Baseline cytogenetics showed KMT2A rearrangement in 27 (57.4%). Baseline myeloid antigen co-expression was seen in 22 of 23 patients with submitted data, but variation in degree of expression across patients and antigens was substantial. The most proximal immunotherapy prior to development of LS was CAR T-cells in 23 (48.9%) and blinatumomab in 24 (51.1%). The median time from the most proximal immunotherapy to development of LS was 1.6 months (range, 7 days-36.5 months). In 7 (29.2%) patients receiving blinatumomab, LS developed during the infusion. LS presented as isolated marrow relapse in 27 (57.4%), isolated CNS in 2 (4.3%), isolated non-CNS extramedullary disease in 3 (6.4%), combined relapse in 14 (29.8%) and unreported in 1. First line treatment for LS was chemotherapy induction in 31 (66.0%), palliative care/no therapy in 8 (17.0%), and alternative therapies in the remaining 8 (17.0%). In 35 (74.5%) patients, remission induction was the goal of first line therapy. Fifteen (31.9%) achieved a complete remission (CR) of whom 2 were treated with palliative intent. Across all patients, 8 (17.0%) are alive in remission, the longest being 4.7 years from LS diagnosis; 2 (4.3%) are alive with active LS and 37 (78.7%) died from LS, their original disease, or complications of treatment of LS (Fig 1B). For those alive in CR (n=8), 7 (87.5%) proceeded to a consolidative SCT for treatment of LS and 1 patient, an octogenarian remains in remission after AML directed therapy. Conclusions: LS is emerging as an important mechanism of immune escape following immunotherapy. Project EVOLVE provides the largest dataset of patients with LS to date. This systematic, international effort reveals substantial complexity and variability in diagnosing and managing LS. Unfortunately, outcomes following LS are grim, underscoring the critical need to identify risk factors of and optimal therapies for this leukemia transformation.
PATH-33. MORPHOLOGY, MOLECULAR FEATURES, AND CLINICAL BEHAVIOR OF METHYLATION CLASS PLEOMORPHIC XANTHOASTROCYTOMA
Dampier, Chris, Shah, Niharika, Galbraith, Kirstyn, Rajan, Sharika, Robinson, Lorraina , Baker, Tiffany , Cathcart, Sahara , Alexandrescu, Sanda , Thomas-Ogunniyi, Jaiyeola , Pytel, Peter , Lopes, Beatriz, Conway, Kyle , Gregory, Jason V. , Abdullaev, Zied , Quezado, Martha , Aldape, Kenneth , Dampier, Christopher H. , Galbraith, Kirstyn, Vaubel, Rachael A. , Ketchum, Courtney , Costa, Felipe D’Almeida , Ferman, Sima , Neto, Osório Lopes Abath , Wadhwani, Nitin R. , Lee, Han, Mao, Qinwen , Marshall, Michael S. , Fernandes, Igor, Cotter, Jennifer A. , Gilani, Ahmed , McCord, Matthew , Thomas, Diana , Gregory, Jason, Andreiuolo, Felipe , Nirschl, Jeffrey , Giannini, Caterina , Snuderl, Matija

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v175-v175

10.1093/neuonc/noad179.0663 Get It

Abstract Methylation profiling has revealed unexpected relationships between traditional histopathology-based versus biologically-based classifications of brain tumors. Methylation class pleomorphic xanthoastrocytoma (mcPXA) comprises tumors with the same methylation signature as classical PXA but with additional morphologic patterns, including overlap with glioblastoma (GBM). To characterize mcPXA, we examined epidemiologic, histologic, and molecular features as well as clinical behavior of a cohort (n=313) of tumors matching to mcPXA by the DKFZ classifier (v12 score &gt;= 0.85). Patient median age was 19 (range 1-73) with a female predominance (178 female/135 male). CDKN2A/B homozygous deletion was observed in 273 (87%) cases. In the subset of cases tested for BRAF p.V600E (n=120), 111 (93%) harbored the mutation. Concomitant chr7+/chr10- was observed in 66 (21%) cases. In the subset of cases tested for TERT promoter mutations (n=50), 11 (22%) harbored the mutation, always with co-occurrence of BRAF p.V600E (11/11) and infrequently with chr7+/chr10- (3/11). MGMT promoter methylation was observed in 40 (13%) cases. Overall and progression-free survival (OS, PFS) in mcPXA were similar to grade 2-3 IDH-mutant astrocytoma (A-IDH). Prognostic factors in mcPXA included GBM-like histopathology (defined as cases diagnosed as GBM prior to methylation profiling), concomitant chr7+/chr10-, and MGMT promoter methylation. GBM-like histopathology was associated with shorter OS (p=0.02) and PFS (p&lt; 0.01) compared to cases without GBM-like histopathology. Concomitant chr7+/chr10- was associated with shorter PFS (p=0.02), and MGMT promoter methylation was associated with shorter OS (p=0.03). Our findings demonstrate that mcPXA tumors affect adolescents and young adults, share molecular features of classical PXA, and manifest clinical behavior similar to classical PXA, but subsets of tumors with atypical features (chr7+/chr10-, MGMT promoter methylation, and/or GBM-like histopathology) are more aggressive. The use of a molecular definition of PXA reveals that this tumor type is more common than previously appreciated and warrants in-depth study for therapeutic options.
PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS
Aldape, Kenneth , Abdullaev, Zied , Turakulov, Rust , Camelo‐Piragua, Sandra , Pytel, Peter , Borys, Ewa, Nix, Stephen, Sloan, Emily A. , Phillips, Kester A., Serafini, Luciano Neder, Trejo‐Lopez, Jorge , Mendez, Joe , Christensen, Brock C. , Colman, Howard , Nguyen, Aivi, Li, Rong , Mandell, James W. , Clarke, Matthew , Mackay, Alan , Helgager, Jeffrey , López, Giselle Y. , Gregorio, Joao Vitor Antunes Marques, Sterman, Hugo , Nasrallah, MacLean P. , Singh, Omkar , Andreiuolo, Felipe , Costa, Felipe D’Almeida , Zhang, Daniel Y. , Fernandes, Igor, Eberhart, Charles G. , Smith-Cohn, Matthew , Neill, Stewart G. , Macaulay, Robert , Colman, Howard , Giannini, Caterina , Kessler, Tobias , Wick, Wolfgang , Jones, Chris , Lee, Han, Perry, Arie , Ahmadian, Saman Seyed , Haeri, Mohammad , Wang, Shih‐Hsiu J. , Dahiya, Sonika , Souza, Andrea Silveira de , Gregorio, João Vitor Antunes Marques , Aboud, Orwa

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v172-v172

10.1093/neuonc/noad179.0653 Get It

Abstract Methylation profiling of brain tumors has revealed novel clusters whose biological and clinical significance is unknown. These include three entities termed by the 12.5 version of the Heidelberg methylation classifier as adult-type diffuse high grade glioma, IDH-wildtype, subtype B (HGG_B), subtype E (HGG_E), and subtype F (HGG_F). We have identified 75 cases belonging to these groups: HGG_B (25 cases, 32% female), HGG_E (40 cases, 42% female), and HGG_F (18 cases, 33% female). Although originally characterized as “adult-type,” we find that 70% of HGG_E cases are pediatric, with a median age at diagnosis of 11 years. HGG_B cases are predominantly seen in young adults, and HGG_F in older adults. The histology varies among methylation classes, with HGG_B cases demonstrating high-grade, predominantly astrocytic, morphology, while HGG_E cases demonstrate high-grade glial histology with distinct nuclear features, and HGG_F cases show highly infiltrative but lower grade glial morphology. Patient outcome data obtained to date shows a collective median survival exceeding 5 years, suggesting re-consideration of the proposed grading for these tumors. MGMT promoter methylation differs across the HGG_B (0%), HGG_E (12%), and HGG_F (0%) subtypes. Mutational analyses show enrichment of TERT promoter mutations in the HGG_F group, while HGG_E samples are enriched for tumors with POLE mutations and elevated tumor mutation burden. HGG_E tumors show epigenetic similarity to pediatric high-grade diffuse gliomas (pedHGG_RTK1A); we therefore propose that HGG_E be considered a pediatric-type HGG. HGG_B tumors show demographic and genomic similarities to high-grade astrocytomas with piloid features, including a subset of cases with CDKN2A/2B loss and ATRX mutation. HGG_F separate into two groups dictated by brain location, and despite the presence of TERT promoter mutations, appear distinct from GBMs. Overall, our work represents an initial effort to understand the morphologic, genomic and clinical characteristics of these previously uncharacterized subtypes of gliomas.
Does COVID-19 impair V̇o2peak in patients with cardiorespiratory disease? Insight from cardiopulmonary responses to maximal exercise pre- and post-illness
Fernandes, Igor A. , Balavenkataraman, Arvind , BONVIE-HILL, NATALIE , Patel, Neal M. , Helgeson, Scott A. , Bonvie-Hill, Natalie E, Helgeson, Scott A , Taylor, Bryan J.

Mayo Clinic

Journal of Applied Physiology | October 19, 2023 | Volume: 135 | Issue: 5 | Pages: 1146-1156

10.1152/japplphysiol.00357.2023 | PMID 37855032 Get It

There is accumulating evidence that reduced exercise capacity is, or can be, an outcome following COVID-19. However, evidence to date relies upon cross-sectional approaches that either do not consider patients with concomitant cardiorespiratory disease or account for pre-infection exercise capacity data. Accounting for V̇o2peak before COVID-19 and including a group of control patients, we find limited evidence for reduced exercise capacity as a sequela of SARS-CoV-2 infection in patients with concomitant cardiorespiratory disease.